COMPANY OVERVIEW

Cancer is the number one killer of people in the prime of life. The medical community is desperately searching for better ways to detect, diagnose, and treat this disease. Genetic technologies are emerging rapidly as powerful tools to identify the disease and guide treatment. The demand for better cancer diagnostics is fueling the development of a market for products using genetic information.

NeoDiagnostix was founded to develop and provide cancer diagnostic testing services using genetic technologies. The Company possesses highly specialized experience and skills in the area of Fluorescent In Situ Hybridization (FISH) techniques and expects to develop and market novel genetic FISH tests for the diagnosis, prognosis and treatment of cancer. By detecting genetic changes in the cells, NeoDiagnostix's tests can identify cancerous cells earlier than traditional testing methods. Earlier detection enables better treatment of the disease and increases the survival rate.

The Company's tests will monitor cancer specific genetic changes in cells using fluorescence-based technology for measuring the amount of cellular DNA and amplification or deletion of individual genes. This technology has several fundamental advantages over currently used approaches for cancer diagnostics.

Current approaches almost exclusively rely on the morphological inspection of patient samples, approaches that are inherently subjective and of low sensitivity. The Company's founders and advisors are among a very small number of world leaders in the development and application of this type of fluorescence-based DNA detection technology.

As a specialized clinical reference laboratory, NeoDiagnostix will offer a set of genetic cancer tests to the medical community. The Company will leverage its specialized knowledge and technology platform to develop a menu of genetic cancer tests and offer these specialized diagnostics across the national medical community. Our expertise in this field and technology platform gives us the ability to develop and provide unique testing services.